Company Description
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
The company’s lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia.
In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.
Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines.
The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026.
The company was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 39 |
| CEO | Timothy Lu |
Contact Details
Address: 2 Corporate Drive, First Floor South San Francisco, California 94080 United States | |
| Phone | 650 239 2030 |
| Website | sentibio.com |
Stock Details
| Ticker Symbol | SNTI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1854270 |
| CUSIP Number | 816944102 |
| ISIN Number | US8169441024 |
| Employer ID | 86-2437900 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Kanya Rajangam M.D., Ph.D. | President, Head of Research and Development and Chief Medical Officer |
| Dr. James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board and Independent Director |
| Jay Cross | Chief Financial Officer |
| Faraz Siddiqui | Senior Vice President of Technical Operations |
| Robert H. Cutler J.D. | Senior Vice President and Head of Legal Affairs |
| Thomas P. Chung | Vice President of Strategic Finance and Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | 8-K | Current Report |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 13, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 13, 2026 | 8-K | Current Report |
| Sep 24, 2026 | EFFECT | Notice of Effectiveness |
| Sep 24, 2026 | DEFM14A | Filing |
| Sep 24, 2026 | 424B3 | Prospectus |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 24, 2026 | PRER14A | Filing |